The following Structured Product Label (SPL) was submitted to the FDA by Amneal Pharmaceuticals Llc for the product Meclizine Hydrochloride (NDC 65162-441). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding description, clinical pharmacology, indications and usage, contraindications, warnings, precautions, adverse reactions, dosage and administration, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Chemically, meclizine HCl, USP is 1-(p-chloro-α-phenylbenzyl)-4-(m-methylbenzyl) piperazine dihydrochloride monohydrate.
C89547bf-figure-01 (Meclizine Hydrochloride Tablets Usp 1)
Inactive ingredients for the tablets are: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium starch glycolate and talc. The 12.5 mg tablets also contain FD&C Blue #1 Aluminum Lake. The 25 mg tablets also contain D&C Yellow #10 Aluminum Lake.
Meclizine HCl is an antihistamine that shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.
Pharmacokinetics
The available pharmacokinetic information for meclizine following oral administration has been summarized from published literature.
Absorption
Meclizine is absorbed after oral administration with maximum plasma concentrations reaching at a median Tmax value of 3 hours post-dose (range: 1.5 to 6 hours) for the tablet dosage form.
Distribution
Drug distribution characteristics for meclizine in humans are unknown.
Metabolism
The metabolic fate of meclizine in humans is unknown. In an in vitro metabolic study using human hepatic microsome and recombinant CYP enzyme, CYP2D6 was found to be the dominant enzyme for metabolism of meclizine.
The genetic polymorphism of CYP2D6 that results in extensive-, poor-, intermediate- and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.
Elimination
Meclizine has a plasma elimination half-life of about 5 to 6 hours in humans.
Management of nausea and vomiting, and dizziness associated with motion sickness.
Meclizine HCl, USP is contraindicated in individuals who have shown a previous hypersensitivity to it.
Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.
Patients should avoid alcoholic beverages while taking this drug.
Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland.
Pediatric Use
Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended in children under 12 years of age.
Pregnancy Use
Pregnancy Category B. Reproduction studies in rats have shown cleft palates at 25 to 50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that meclizine increases the risk of abnormalities when administered during pregnancy. Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine, or any other medication, should be used during pregnancy only if clearly necessary.
Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when meclizine is administered to a nursing woman.
Hepatic Impairment
The effect of hepatic impairment on the pharmacokinetics of meclizine has not been evaluated. As meclizine undergoes metabolism, hepatic impairment may result in increased systemic exposure of the drug. Treatment with meclizine should be administered with caution in patients with hepatic impairment.
Renal Impairment
The effect of renal impairment on the pharmacokinetics of meclizine has not been evaluated. Due to a potential for drug/metabolite accumulation, meclizine should be administered with caution in patients with renal impairment and in the elderly as renal function generally declines with age.
Drug Interactions
There may be increased CNS depression when meclizine is administered concurrently with other CNS depressants, including alcohol, tranquilizers and sedatives. (see WARNINGS)
Based on in vitro evaluation, meclizine is metabolized by CYP2D6. Therefore there is a possibility for a drug interaction between meclizine and CYP2D6 inhibitors.
Anaphylactoid reaction, drowsiness, dry mouth, headache, fatigue, vomiting and, on rare occasions, blurred vision have been reported.
Motion Sickness
The initial dose of 25 mg to 50 mg of meclizine HCl tablets, USP should be taken one hour prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.
Meclizine HCl Tablets, USP 12.5 mg, are supplied as light blue colored, oval shaped tablets with “AN 441” debossed on one side and plain on the other side.
They are available as follows:
Bottles of 30: NDC 65162-441-03
Bottles of 100: NDC 65162-441-10
Bottles of 500: NDC 65162-441-50
Bottles of 1000: NDC 65162-441-11
Blister packs: NDC 65162-441-60
(Packages of 100 unit doses, 10 cards of 10 tablets each)
Meclizine HCl Tablets, USP 25 mg, are supplied as light yellow colored, oval shaped tablets with “AN 442” debossed on one side and plain on the other side.
They are available as follows:
Bottles of 30: NDC 65162-442-03
Bottles of 100: NDC 65162-442-10
Bottles of 500: NDC 65162-442-50
Bottles of 1000: NDC 65162-442-11
Blister packs: NDC 65162-442-60
(Packages of 100 unit doses, 10 cards of 10 tablets each)
Meclizine HCl Tablets, USP 50 mg, are supplied as white, oval shaped, partially bisected tablets with “AN 444” debossed on one side and plain on the other side.
They are available as follows:
Bottles of 30: NDC 65162-444-03
Bottles of 100: NDC 65162-444-10
Bottles of 500: NDC 65162-444-50
Bottles of 1000: NDC 65162-444-11
Blister packs: NDC 65162-444-60
(Packages of 100 unit doses, 10 cards of 10 tablets each)
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C [See USP Controlled Room Temperature].
Dispense in a tight, light-resistant container.
Rx only
Distributed by:
Amneal Pharmaceuticals
Bridgewater, NJ 08807
Rev. 10-2015-00
30 Ct. (Meclizine Hydrochloride Tablets Usp 2)
30 Ct. (Meclizine Hydrochloride Tablets Usp 3)
30 Ct. (Meclizine Hydrochloride Tablets Usp 4)
* Please review the disclaimer below.
